SunTrust Robinson Reports That They Have Upgraded Bristol Myers (NYSE:BMY) Shares

January 19, 2018 - By Hazel Jackson

  SunTrust Robinson Reports That They Have Upgraded Bristol Myers (NYSE:BMY) Shares

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It increased, as 62 investors sold Bristol-Myers Squibb Company shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported.

White Pine Limited Com owns 41,696 shares or 0.01% of their US portfolio. Hanson & Doremus Inv Mngmt has invested 0.77% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Garrison Bradford & Assocs Incorporated owns 4,000 shares. Reynders Mcveigh Management Ltd holds 28,771 shares. Lmr Partners Llp reported 7,308 shares. Granite Point Lp stated it has 0.4% in Bristol-Myers Squibb Company (NYSE:BMY). Ingalls And Snyder Ltd Liability Co invested in 195,346 shares or 0.65% of the stock. Marco Invest Limited Liability invested in 0.28% or 28,125 shares. South Dakota Investment Council reported 101,600 shares or 0.13% of all its holdings. Prelude Llc holds 0.13% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 21,985 shares. Fmr Ltd Com invested 0.24% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). First Mercantile Tru invested in 5,275 shares. Rothschild Inv Il reported 87,799 shares. Cypress Capital Management Ltd Liability Com (Wy) stated it has 3,270 shares or 0.25% of all its holdings. Georgia-based Voya Ltd Com has invested 0.11% in Bristol-Myers Squibb Company (NYSE:BMY).

Since September 6, 2017, it had 1 insider purchase, and 2 selling transactions for $646,385 activity. The insider Caldarella Joseph C sold 9,340 shares worth $560,400. 5,300 shares were sold by Lynch Thomas J. Jr., worth $335,172.

Bristol Myers (NYSE:BMY) Stock Upgrade

In analysts note made public on Monday, 30 October, SunTrust Robinson upgraded their rating for shares of Bristol Myers (NYSE:BMY) to a “Buy”.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It increased, as 62 investors sold Bristol-Myers Squibb Company shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported.

White Pine Limited Com owns 41,696 shares or 0.01% of their US portfolio. Hanson & Doremus Inv Mngmt has invested 0.77% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Garrison Bradford & Assocs Incorporated owns 4,000 shares. Reynders Mcveigh Management Ltd holds 28,771 shares. Lmr Partners Llp reported 7,308 shares. Granite Point Lp stated it has 0.4% in Bristol-Myers Squibb Company (NYSE:BMY). Ingalls And Snyder Ltd Liability Co invested in 195,346 shares or 0.65% of the stock. Marco Invest Limited Liability invested in 0.28% or 28,125 shares. South Dakota Investment Council reported 101,600 shares or 0.13% of all its holdings. Prelude Llc holds 0.13% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 21,985 shares. Fmr Ltd Com invested 0.24% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). First Mercantile Tru invested in 5,275 shares. Rothschild Inv Il reported 87,799 shares. Cypress Capital Management Ltd Liability Com (Wy) stated it has 3,270 shares or 0.25% of all its holdings. Georgia-based Voya Ltd Com has invested 0.11% in Bristol-Myers Squibb Company (NYSE:BMY).

Since September 6, 2017, it had 1 insider purchase, and 2 selling transactions for $646,385 activity. The insider Caldarella Joseph C sold 9,340 shares worth $560,400. 5,300 shares were sold by Lynch Thomas J. Jr., worth $335,172.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $62.53’s average target is 0.84% above currents $62.01 stock price. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Wednesday, August 16. BMO Capital Markets has “Sell” rating and $49.0 target. The rating was upgraded by Jefferies to “Buy” on Monday, December 19. The company was initiated on Wednesday, April 26 by Robert W. Baird. As per Monday, October 23, the company rating was maintained by Leerink Swann. Cowen & Co maintained Bristol-Myers Squibb Company (NYSE:BMY) on Thursday, October 19 with “Hold” rating. Jefferies maintained it with “Buy” rating and $6300 target in Monday, July 17 report. The firm has “Buy” rating given on Thursday, July 27 by Leerink Swann. As per Thursday, August 27, the company rating was maintained by Jefferies. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Buy” rating by Berenberg on Friday, January 22. Jefferies maintained the stock with “Hold” rating in Tuesday, June 14 report.

The stock increased 0.29% or $0.18 during the last trading session, reaching $62.01. About 3.89 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since January 19, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on January, 25. They expect $0.67 EPS, up 6.35 % or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10 billion for 23.14 P/E if the $0.67 EPS becomes a reality. After $0.75 actual EPS reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -10.67 % negative EPS growth.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $101.49 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 24.33 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

More important recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Livetradingnews.com which released: “Bristol-Myers Squibb Co (NYSE:BMY) Bullish Divergence” on January 09, 2018, also Nasdaq.com published article titled: “Ex-Dividend Reminder: Bristol-Myers Squibb, Brixmor Property Group and Kite …”, Reuters.com published: “Bristol-Myers sees $3 billion tax hit in fourth quarter 2017” on January 05, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) was released by: Streetinsider.com and their article: “Bristol-Myers Squibb (BMY) PT Jumps to $60 At Deutsche Bank” with publication date: January 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: